Shenzhen Salubris Pharmaceuticals Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS10
PHASE 3 / 2-30
RECRUITING3
READOUTS ≤12 MONTHS5
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| SAL-0951 tablets 4mg NCT06737081 |
P2 | Recruiting | Anemia | 60 | 2025-12-31 |
| SAL0120 1mg NCT07716618 |
P2 | Active, not recruiting | Chronic Kidney Disease | 320 | 2026-05-27 |
| SAL056 56.5μg NCT07579936 |
P2 | Recruiting | Postmenopausal Women With Osteoporosis | 200 | 2026-07-30 |
| GW906 NCT07835971 |
P2 | Active, not recruiting | Hypertension | 319 | 2026-09-15 |
| SAL0137 Dose 1 NCT07729475 |
P2 | Not yet recruiting | Elevated Lipoprotein(a) | 120 | 2026-12-12 |
| SAL0140 NCT07654140 |
P2 | Recruiting | Uncontrolled Hypertension | 252 | 2027-03-01 |
| SAL0140 Tablets NCT07646535 |
P2 | Not yet recruiting | Primary Aldosteronism | 50 | 2027-04-01 |
| GW906 NCT07835984 |
P2 | Not yet recruiting | Hypertension | 560 | 2027-10 |
| SAL0140 Tablets NCT07647133 |
P2 | Not yet recruiting | Chronic Kidney Disease | 249 | 2027-10-08 |
| SAL0150 dose 1 NCT07923357 |
P2 | Not yet recruiting | Type 2 Diabetes Mellitus (T2DM); Type 2 Diabetes | 364 | 2027-11-30 |